Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Cartesian Therapeutics, Inc. reported revenue of $3M, down 92.8% year over year. Operating margin was -5127.1% and net margin -4658.6%, on a free-cash-flow margin of -2838.6% with capital expenditure at 195.0% of revenue. Every figure is computed directly from RNAC's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $3M | -5127.1% | -4658.6% |
| FY2024 | $39M | -112.8% | -199.0% |
| FY2023 | $26M | -332.3% | -844.9% |
| FY2022 | $111M | 13.1% | 31.9% |
| FY2021 | $85M | -5.4% | -30.2% |
How does RNAC compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.